Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : YOLT-101
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Recipient : YolTech Therapeutics
Deal Size : $145.3 million
Deal Type : Licensing Agreement
YolTech Signs Licensing Deal with Salubris For YOLT-101 in China
Details : YolTech will continue to advance the preclinical development of YOLT-101, while Salubris will be responsible for preparing and conducting clinical trials within the licensed territory.
Product Name : YOLT-101
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
August 27, 2024
Lead Product(s) : YOLT-101
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Recipient : YolTech Therapeutics
Deal Size : $145.3 million
Deal Type : Licensing Agreement
Lead Product(s) : Enarodustat
Therapeutic Area : Hematology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ONNARO (enarodustat) is a new generation of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), was approved for the treatment of non-dialysis-dependent patients with anemia caused by chronic kidney disease.
Product Name : Onnaro
Product Type : Small molecule
Upfront Cash : Not Applicable
June 09, 2023
Lead Product(s) : Enarodustat
Therapeutic Area : Hematology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : JK07
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Recipient : Salubris Biotherapeutics
Deal Size : $35.0 million
Deal Type : Financing
Details : The financing will be used to advance and accelerate JK07, including the planned initiation of the first Phase 2 study in HFrEF and the continuation of the ongoing Phase 1b clinical trial in heart failure with preserved ejection fraction.
Product Name : JK07
Product Type : Large molecule
Upfront Cash : Undisclosed
March 28, 2023
Lead Product(s) : JK07
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Recipient : Salubris Biotherapeutics
Deal Size : $35.0 million
Deal Type : Financing
Lead Product(s) : JK07
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Carlyle
Deal Size : $260.0 million
Deal Type : Acquisition
Carlyle to Acquire 5% Stake in Salubris, a Leading Biopharmaceutical Company in China
Details : Salubris has developed a comprehensive innovative pipeline in the treatment of chronic diseases, including JK07, an innovative biologic drug treating heart failure which has filed for clinical trial approvals in both China and the United States.
Product Name : JK07
Product Type : Large molecule
Upfront Cash : Undisclosed
September 01, 2020
Lead Product(s) : JK07
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Carlyle
Deal Size : $260.0 million
Deal Type : Acquisition
Reset All
